Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.5022 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5022-5022 ◽

Author(s):

J.-M. Ferrero ◽

B. Weber ◽

D. Lepille ◽

H. Orfeuvre ◽

M. Combe ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5022 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5022-5022 ◽

Author(s):

J.-M. Ferrero ◽

B. Weber ◽

D. Lepille ◽

H. Orfeuvre ◽

M. Combe ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

Annals of Oncology ◽

10.1093/annonc/mdl376 ◽

2007 ◽

Vol 18 (2) ◽

pp. 263-268 ◽

Author(s):

J.-M. Ferrero ◽

B. Weber ◽

J.-F. Geay ◽

D. Lepille ◽

H. Orfeuvre ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin ◽

Late Relapse ◽

Second Line ◽

Second Line Chemotherapy ◽

Line Chemotherapy

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial

Annals of Oncology ◽

10.1093/annonc/mdl079 ◽

2006 ◽

Vol 17 (6) ◽

pp. 957-961 ◽

Author(s):

J. Sehouli ◽

G. Oskay-Özcelik ◽

J. Kühne ◽

D. Stengel ◽

H.-J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Multicenter Phase

Download Full-text

Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.09.033 ◽

2009 ◽

Vol 112 (1) ◽

pp. 35-39 ◽

Author(s):

Sheng-Mou Hsiao ◽

Chi-An Chen ◽

Ho-Hsiung Lin ◽

Chang-Yao Hsieh ◽

Lin-Hung Wei

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Sensitive ◽

Download Full-text

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.08.020 ◽

2006 ◽

Vol 100 (2) ◽

pp. 318-323 ◽

Author(s):

M.O. Nicoletto ◽

C. Falci ◽

D. Pianalto ◽

G. Artioli ◽

P. Azzoni ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5072 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5072-5072 ◽

Author(s):

J. Sehouli ◽

G. Oskay ◽

I. Katsares ◽

P. Klare ◽

H. J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin

Download Full-text

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5045 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5045-5045 ◽

Author(s):

R. W. Naumann ◽

R. L. Coleman ◽

R. A. Burger ◽

T. J. Herzog ◽

R. Morris ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.03.470 ◽

2014 ◽

Vol 133 ◽

pp. 178-179

Author(s):

T.J. Herzog ◽

K. Anderson ◽

J. Wang ◽

R. Xu

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Model Prediction ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Folate Receptor ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Positive Target

Download Full-text

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

ESMO Open ◽

10.1016/j.esmoop.2021.100212 ◽

2021 ◽

Vol 6 (4) ◽

pp. 100212

Author(s):

J.A. Perez-Fidalgo ◽

A. Cortés ◽

E. Guerra ◽

Y. García ◽

M. Iglesias ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant

Download Full-text